Learners are aware HIV develops resistance, but as new and increasingly complex antiretroviral combinations become FDA approved, learners may not be aware of emerging resistance patterns, and may not be familiar with changing technology to assess resistance in patients who are virally suppressed.

Speaker: Christopher James, PharmD, AAHIVP